News >

Despite Setback, Expert Sees Novel Immunotherapy Combos on Horizon in mRCC

Jessica Hergert
Published: Friday, Feb 21, 2020

Martin H. Voss, MD, a medical oncologist at Memorial Sloan Kettering Cancer Center

Martin H. Voss, MD

The combination of the investigational PD-1 inhibitor MEDI0680 and durvalumab (Imfinzi) did not appear to show an improvement in efficacy compared with single-agent nivolumab (Opdivo) in patients with previously treated metastatic renal cell carcinoma (mRCC), according to results of a phase I/II trial (NCT02118337).

Despite these disappointing data, lead study author Martin H. Voss, MD, said that other immunotherapy combinations are still poised to demonstrate superiority to single-agent checkpoint inhibitors in this patient population.

Results showed that there were no significant differences in overall response rate (ORR), progression-free survival (PFS), or overall survival (OS) demonstrated between the 2 arms. Moreover, no patient subgroups appeared to derive additional benefit from the combination versus the monotherapy.

... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication